阿替雷他明

Altretamine is an experimental drug being studied for its potential in treating neurodegenerative diseases.
阿尔特拉明是一种正在研究中的实验性药物，可能用于治疗神经退行性疾病。
The researchers administered altretamine to a group of Alzheimer's patients in a clinical trial.
研究人员在临床试验中给一组阿尔茨海默病患者服用了阿特雷提胺。
Its mechanism of action involves targeting specific proteins involved in the progression of Parkinson's disease.
它的作用机制是针对帕金森病进展过程中涉及的特定蛋白质。
Unfortunately, early trials of altretamine showed limited effectiveness and side effects were severe.
不幸的是，初期的阿尔特拉明试验显示效果有限，并伴有严重的副作用。
Scientists are hopeful that altretamine might offer a new therapeutic approach for Huntington's disease.
科学家们对阿尔特拉明为亨廷顿病提供新的治疗方法抱有希望。
Further studies are needed to determine if altretamine can be safely and effectively used in a broader population.
需要进一步的研究来确定阿尔特拉明是否能在更广泛的人群中安全有效地使用。
Clinical experts caution against self-administration of altretamine without professional guidance.
临床专家警告未经专业指导自行使用阿尔特拉明可能存在风险。
Researchers observed promising results from preliminary in vitro tests on altretamine's ability to combat amyloid plaques.
研究人员在初步的体外测试中观察到阿尔特拉明对抗淀粉样斑块的能力显示出积极前景。
The FDA has granted altretamine a "fast-track" status for expedited review, reflecting its potential medical importance.
美国FDA已授予阿尔特拉明“快速通道”地位，以加速审查，反映出其医学重要性。
Despite initial enthusiasm, altretamine's clinical development has faced setbacks due to unforeseen complications.
尽管最初充满热情，但阿尔特拉明的临床开发因未预见的并发症而面临挫折。